Expert Interview
A Second Look: Examining the recent Top-line Data from Phase 1/2 Proof-of-Concept Study of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults.
Ticker(s): PCVX, MRK, PFE- Internal Medicine
- Treats ~30 patients per month with pneumococcal disease
- Sent Topline data for her review
- Dr. Espinosa earned her medical degree from St. Louis University College of Medicine in the Philippines. She completed her internship at Akron General Medical Center in Ohio
What is the current standard care for someone with Pneumococcal disease
Added By: max_adminOn a scale of 1-10 how excited are you regarding Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine Candidate?
Added By: max_adminHow would a new vaccine for pneumococcal disease change your preference for treatment?
Added By: max_adminDo you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
